Clinical Trial Update: ADVM-022 Intravitreal Gene Therapy for DME [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ADVM-022 intravitreal gene therapy for diabetic macular edema and diabetic retinopathy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Diabetic Retinopathy

Drugs mentioned

• ADVM-022

Snippet

Sponsor: Adverum Biotechnologies, Inc. | Conditions: Diabetic Macular Edema, Diabetic Retinopathy | Phase 2 | Status: COMPLETED | Results posted: 2025-07-10